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Abstract
A recent surge of research in the field of tissue engineering has contributed to the
development of novel biomaterials for restoring or replacing diseased cardiovascular tissues. In
an effort to control biodegradability, a new class of polymers known as poly (ester amide)s
(PEAs) are being studied as they show promising results for their use as biomaterials.
The work in this thesis focuses on a PEA that was synthesized from the a-amino acid Lalanine, 1,8-octanediol and sebacoyl chloride. Following detailed characterization, the
synthesized PEA was used for fabricating of fibrous scaffolds with a blend of PCL by
electrospinning. A number of parameters were studied in order to optimize the electrospinning
process as well as fibre size; namely that of solution concentration and distance from collector.
With increasing solution concentration, an increase in fibre diameter as well as pore size was
observed. Conversely, increasing distance from the needle tip to the collector reduced fibre
diameter for up to 10 cm then diameter increased up to 14cm from collector. In addition,
qualitative and quantitative degradation of PEA and PEA-PCL polymer blend discs were also
assessed and, results show that degradation proceeded primarily through fibre fusing and surface
erosion. PEA quantity had a significant effect on degradation time where higher PEA contents
accelerated the degradation. Finally, cell studies using human coronary artery smooth muscle
cells (HCASMC) were conducted to assess its suitability for proliferation and gene expression
and, consequently, use in vascular tissue engineering. MTT assay showed that the fibres were not
cytotoxic. Furthermore, cells showed strong attachment after a 4 and 7 day culture. Finally,
Western blot analysis revealed that elastin protein gene expression was enhanced on these fibres.
Keywords: Biomaterials, Poly (ester amide)s, electrospinning, vascular smooth muscle cells,
elastin
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CHAPTER 1
1 Introduction
Cardiovascular diseases (CVDs), defined as essentially all the health conditions that
affect the heart muscle, heart valves, and blood vessels, account for nearly 40% of total deaths in
North America every year.1 These typically include coronary heart disease and myocardial
infarctions, with atherosclerosis serving as the primary cause. Hardening of the artery wall due
to the buildup of fatty materials leads to coronary occlusion and strokes, whereas loss of vessel
elasticity causes aneurysms. It is estimated that an average of a million Americans succumb to
heart failure every year; these diseases account for 34% of all mortality.1 Around 500,000
Americans and 23,000 Canadians undergo coronary heart bypass surgeries every year. ’ In
addition, similar numbers of patients are diagnosed with heart disease every year. In order to
battle this rapidly progressing condition, science and medicine have pushed the limits of
biological systems to create new surgical procedures and replacement therapies.
1.1 Intervention Approaches in Cardiovascular Medicine
A preventative approach to the treatment of cardiovascular disease is advised by most
health practitioners, which include strict regulations to diet and lifestyle choices. Although this
may reduce the risk of the disease significantly, patients often find themselves requiring at least
one form of therapy. A myocardial infarction, or heart attack, occurs at the onset of occlusion of
one or more blood vessels that directly supplies to the heart.4 If the blood flow is not restored
immediately, cell death occurs within the oxygen-deprived heart muscle. Mature contracting and
terminally differentiated cardiac cells, otherwise known as cardiomyocytes, cannot divide and
therefore the heart tissue is beyond repair. The final result of the infarction is the formation of
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scar tissue around the heart; an occurrence that is highly undesirable as scar tissue does not have
the contractile, mechanical or electrical functions of a healthy myocardium.4
Current treatment of severe occlusion involves bypass grafts. These are usually of three
different kinds: autografts, which are from the patient’s own body; allografts, which are obtained
from a matching healthy patient; xenografts, which are from a different species, mostly bovine or
porcine tissues and finally, synthetic prostheses.5 It can often be argued that percutaneous
intervention therapies such as balloon angioplasty remain a minimally invasive procedure in an
attempt to avert surgery as a treatment. However, often in more advanced progressions of the
disease, this option is not generally recommended by clinicians.6 The utilization of stents and
drug eluting stents are also commonly adopted methods of therapy.6
In terms of other methods that are currently under extensive investigation, stem cell and
gene therapies to induce angiogenesis of arteries using endothelial growth factors and the
development of novel synthetic biomaterials that are used as scaffolding for differentiated
cardiovascular cells or stem cells are the most promising.6
1.1.1

The Regenerative Approach
A major drawback of relying on surgical intervention alone is the lack of autograft and

allograft donors and complications associated with post-operative immunosuppressive
treatments. As a result, researchers and surgeons are continuously working on finding new
methods to revive a damaged tissue. For example, the use of embryonic stem cells that can be
differentiated into cardiomyocytes made cellular therapy a potential treatment for cardiovascular
diseases, such as myocardial ischemia or infarctions. Recently, research has ventured into
utilizing adult stem cells from bone marrow and adipose tissues. The typical mode of

2

administration of cell therapy is direct injection into the ventricular wall or into the coronary
vessels and, is known as cardiomyoplasty.6 Cellular therapy is a common paradigm used in
tissue engineering and regenerative medicine and is often combined with tissue replacement
approaches. It is advantageous in the sense that it is a minimally invasive surgery if the cells can
n

be injected intravenously. ’

o

Adipose tissue derived stem cells and bone-marrow derived

mesenchymal stem cells are extensively studied. In the case of the former, easily accessible fat
and its abundance throughout the body makes it a useful source of stem cells. 9 In one study, it
was found that adipose lineage cells could function as progenitors for endothelial cells by
forming a vascular-like structure in a Matrigel plug and promote neovascularization.9 Another
study demonstrated the potential of bone marrow cells forming myocardial tissue in infarcted
hearts and to restore their function.10
Cellular therapy could potentially be effective as it can provide a renewable source of
proliferative cells and differentiated cardiomyocytes which result in the regeneration of blood
vessels to support and nourish these newly formed cardiomyocytes and the surrounding ischemic
myocardium. In spite of the reported efficacy of this method, controversy surrounds the use of
stem cells in cardiovascular tissue regeneration; in addition, there are many unanswered
questions regarding its method of administration and safety.11
1.1.2

The Tissue Repair Approach
Given the lack of understanding, limited success, and controversy of stem cell therapy as

a valuable method of intervention, a reparative approach is often studied. Vascular occlusions are
often repaired by a minimally invasive balloon angioplasty. 12 In this method, a balloon attached
to a catheter is guided to the site of the blockage and inflated to push the plaque against the
vascular wall. This compression effect widens the narrowed vessel and increases the perfusion,
3

thus preventing further damage to the tissue.12 Although the procedure is in principle a
successful first-line therapy, it is not without problems. It has a tendency to lead to subsequent
recoil of the vascular wall due to poor wall mechanics and restenosis of the lumen due to
unregulated cell proliferation. In order to overcome these limitations, drug eluting stents are
frequently deployed during the intervention. However, there are still several issues associated
with this therapy, mostly that of delayed healing due to endothelial dysfunction.13 Another
concern is late stage restenosis and thrombosis. For example, in one study, if anti-platelet therapy
was stopped, which occurred for some patients, occlusion was observed, which was then
reversed by another percutaneous intervention, which is also prone to restenosis.13
1.1.3

The Replacement Approach and Tissue Engineering
When both the regenerative and the repair approaches fail to deliver the intended

outcome, surgical replacement or bypass surgery of blood vessel segments is the most common
intervention for coronary and peripheral atherosclerotic diseases. With the rapid growth of the
elderly segment of the population, the number of coronary artery replacement interventions is
expected to increase rapidly.14 An ideal vascular graft should have adequate mechanical strength,
good blood compatibility and compliance.15 Although autologous segments of the commonly
used saphenous vein or mammary artery are preferred for coronary artery bypass grafts, they are
not always available and the failure rate is high. 16 Venous and arterial allograft and xenograft
vessels frequently suffer from rejection; poor patency and compliance mismatch.

Synthetic

grafts made from expanded polytetrafluoroethylene (ePTFE, Teflon) and polyethylene
terephthalate (PET, Dacron) work well for large diameter vascular grafts (>6 mm ID) where the
blood flow rate is high, but results in small diameter coronary artery graft applications (<4 mm
ID) have been disappointing.18 Obviously, functional restoration of diseased vascular tissues
4

remains a challenge and none of the existing surgical interventions provide a satisfactory
outcome. Tissue Engineering has the potential to develop novel approaches to fabricate orderly
and mechanically competent autologous vessels via scaffold guided in vitro engineering
alternatives. Tissue engineering is an interdisciplinary field that applies the principles of
engineering and life sciences toward the development of biological substitutes that restore
maintain or improve tissue function or a whole organ.15 It encompasses regenerative procedures
and development of tissue for therapeutic benefits.19,20
In the most frequent paradigm, tissue engineering consists of a scaffold that is porous and
fabricated from a biomaterial that can be natural or synthetic and aids in the adhesion,
proliferation and migration of cells. It is advantageous in the sense that it can be coupled with
cellular therapy, where mesenchymal stem cells, bone marrow cells, endothelial progenitor cells
or adipose stem cells can be seeded onto the scaffold to promote differentiation and proliferation,
but would still require surgical placement into the patient. Biomaterials would then typically
need to be compatible with the specific cells and match the mechanical properties of the tissue in
question, be it myocardium patches, blood vessels or heart valves. These materials are discussed
at length in a later section of this chapter.
1.2

Paradigms of Tissue Engineering
Since the development of tissue engineering, several commonly adopted strategies have

been developed. These are cell transplantation, scaffold implantation, a combination of the two
or, in vitro tissue engineering.
As mentioned in the preceding section, cell transplantation typically involves the
injection of cells into the area of a damaged tissue.4,6 In myocardial tissue engineering, it is
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possible to isolate mesenchymal stem cells from adult bone marrow and inject it into the affected
myocardium. A typically minimally invasive procedure, cell transplantation is an appealing
option. However, there is absolutely no guarantee that the injection of cells into the area will
form a functional network of cells. 2 The biggest concern in cellular therapy is immune rejection
which could eventually lead to loss of specified cellular function.19, 21 Efforts to improve
immune rejection are currently being looked into, possibly with simultaneous administration of
immunosuppressant along with the cell injections.9, 10 Another potential issue in the future is
commercial availability. If clinical trials are successful, it may be difficult to meet commercial
demand for clinical need of cardiovascular treatments.4
A very common strategy of tissue engineering involves the implantation of a scaffold into
the host model that helps repopulate and regenerate damaged tissue.

Regeneration is achieved

by implantation of a resorbable matrix that remodels in vivo and thus produce a fully functional
heart valve complete with connective tissue proteins.

Repopulation is yet another approach,

where a decellularized connective tissue is prepared for human cell proliferation thereby reviving
the cellular matrix from within the patient and creating an entirely functional tissue.

Sadly, the

studies resulted in several failures and early patient deaths and efforts are being made to invest
more time and money into scaffold implantation research. A major contributor to the failure of
this method is poor cell recruitment and maintenance, as it is entirely dependent on the native
cells to populate the valve.
Another form of implantation is cell-seeded scaffolds, where a matrix substrate is seeded
with cells prior to implantation into the host, without primary in vitro maturation.22,24 It typically
consists of a substrate on which growth factors are combined; so upon implantation, cells from
the body are further recruited to the site of scaffold to mature and form tissue. 22 The
6

incorporation of vascular endothelial growth factor (VEGF) to provide controlled release into a
polymeric substrate has been reported. Release of bioactive VEGF was confirmed using the
specified assays and demonstrated that the growth factor retained its angiogenic properties and
encouraged neovascularization around the scaffold.

A key issue in these studies is generally

matching growth factor release to the kinetics of physiological responses.
Lastly, in vitro tissue engineering is the most commonly utilized paradigm. It typically
involved seeding cells on a scaffold that is usually a polymeric substrate, either from naturally
occurring materials or synthetic and placing it in a bioreactor until complete maturation. The
seeded cells will infiltrate the scaffolds and proliferate while the scaffold undergoes degradation,
if required. This way, cells are able to lay down their own ECM and the substrate acts as a
temporary matrix until new ECM is formed.

Finally, the matured tissue is ready for

implantation into the host, allowing further in vivo maturation. Points of consideration with these
studies are the choice of cells, scaffolds and bioreactors that are used.22,25 Isolated multipotent
cell varieties are usually utilized as they can differentiate into a variety of tissue specific cells
and do not cause significant host responses. These cells would typically include fibroblasts and
endothelial cells, where in vitro proliferation is quick, while using adult smooth muscle cells or
cardiomyocytes provide almost no proliferation. In addition, the scaffold material is extremely
important as it regulates cell adhesion and proliferation. Furthermore, if a biodegradable
substrate is required so the eventual tissue is completely comprised of native ECM, the
supporting material should be tailored accordingly. ’

Finding the right material thus remains

one of the key challenges faced when pursuing in vitro tissue engineering.
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1.2.1 Clinical Need for Vascular Tissue Engineering
As mentioned earlier, the prevalence of cardiovascular disease in North America is high
and subsequently contributes to high mortality rates.1 It is a tremendous economic burden and
therefore, new medical advances are emerging to tackle this burden. With the development of
percutaneous interventions such as balloon angioplasty and stent placements, the burden was
thought to have been considerably lowered; however, it remains that bypass surgery to repair
coronary artery disease is probably the most routine method adopted by clinicians.14 Vascular
grafts are usually comprised of saphenous vein, which has shown to lead to aneurysms in some
patients due loss of elasticity when exposed to arterial pressure.

As stated above, synthetic

vascular grafts are used despite their poor performances.28 Thus, the need to improve current
therapeutic approaches is high. Surgeons, clinical researchers and biomedical engineers are
always exploring new methods, which is where tissue engineering for vascular replacement
shows immense promise. Providing cells with a substrate that mimics the physiological matrix
and having the ability to repair, grow and remodel create the premise for an efficient approach to
complete tissue fabrication and functionality. Although cardiovascular tissue engineering is far
from success, studies are showing promising results as to its viability in future vascular
intervention. ’ ’

For example, development of an autologous tissue-engineered graft for

hemodialysis patients in a multicentre clinical trial showed maintenance of patency upto six
months after implantation.31 The potential benefit of engineered vascular tissues is significant.
Currently patients who had vascular surgery must take life-long anticoagulant drugs to mitigate
graft rejection.24 Patient-specific tissue-engineered blood vessels will eliminate the need of drugs
since the tissue will not be rejected. The potential impact of the proposed research is even more
significant for pediatric patients since tissue-engineered vessels have the capacity to grow, repair,
and remodel as required with normal development.
8

1.2.2 Three Dimensional Tissue Model
In addition to having a clinical application, engineered vascular tissues could have
diagnostic applications for testing drug uptake and metabolism, toxicity, and pathogenicity
contributing to our understanding of genetic or environmental factors regulating treatment
outcomes.

The use of cell and organ culture in combination with animal models to study

vascular diseases (e.g. atherosclerosis, post angioplasty restenosis, and hypertension) in an
attempt to develop therapeutics is not new but employing engineered human vascular tissues for
this role is a novel concept. ’

While conventional 2D cell cultures are indispensable to our

understanding of tissue morphogenesis and function in physiological and pathological states,
they do not accurately replicate the 3D microenvironment of human tissues. For example, 2D
culturing of vascular cells for studying intimal hyperplasia without the arterial wall structure and
extracellular matrix

cannot recapitulate the intricate vascular wall mechanics

and

morphogenesis.32, 34 Similarly, animal organ cultures and whole animal models do not
completely mimic the human biology due to the inevitable inter-species difference. Studies using
closely related nonhuman primates are constrained by limited availability, legal restrictions,
ethical concerns, and high cost.
When studying human vascular diseases and therapeutics, a realistic model is a human
tissue but, the inability to experiment directly on human subjects limits this progress. Thus the
need for an engineered human vascular tissue model to close this gap is of vital importance.
Engineered vascular tissues are not likely to replace animal or human subjects; however, they
have the potential to provide high throughput, substantive, and detailed information regarding
very specific conditions under controlled environments. The significance is far-reaching as these
"made to order" vascular tissues comprising cells (smooth muscle and endothelial cells) and
9

ECM (elastin and collagen) could serve as a powerful high-throughput tool to study disease
models and therapeutic outcomes that are not possible with animal-based models. ’

In this

context, engineered vascular tissue technology may be used both to validate drug targets and to
optimize loads. This allows for cardiovascular drug screening in a more controlled and efficient
way than can be performed using a traditional whole animal approach, thereby minimizing the
number of laboratory animals used and decreasing the overall cost of performing research.35 The
use of 3D engineered tissue to reduce the cost and time required for physiological genomic
research is another niche which is unexplored. Recently engineered 3D tissues such as cardiac
patch 37, lung tissue 38, cornea 39 and solid tumor models 40 have emerged as powerful tools for
drug discovery and to study cells in 3D.41 In comparison with 2D cultures, 3D cell models create
a more realistic representation of real tissues, which is critical for many important cell functions,
including morphogenesis, cell metabolism, gene expression, differentiation, and cell-cell
interactions. 41
1.3

Requirements of Tissue Engineering Scaffolds
Tissue engineered scaffolds act as a support mechanism during tissue repair, regeneration

or fabrication process, or serve as a complete replacement to the damaged tissue. Scaffolds can
either be fabricated from naturally occurring polymers such as elastin 42, collagen 43, silk 44 or
O

more commonly, from synthetic polymeric biomaterials. Different configurations of scaffolds
can be constructed and it is often dependent on the type of engineering application it is required.
In order for a tissue to be constructed, the biomaterial of choice needs to fulfill certain
characteristics that allow for maximum performance. These criteria are essentially used as a
checklist when developing a new scaffold and are extremely important.
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Fabrication methods ensure a diverse range of configurations; it also helps control
parameters such morphology and mechanical properties.

For example, electrospinning is able

to provide a fibrous mesh where pore size and fibre size can be tailored to be on the nano-scale.45
In addition to modification of scaffold architecture based on its application, porosity of the
scaffold also needs to be considered. This includes pore size measurements as well as the
distribution of the average pore size across the construct, to promote cell infiltration and
organization.45-47 Optimization of surface chemistry will also allow better cell adhesion,
proliferation and migration.45,48
Given that these scaffolds are being designed for use in medicine, the materials used
obviously need to be biocompatible. Biodegradability is also another desired characteristic,
wherein degradation and tissue regeneration occur at a constant and predictable relationship.
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Mechanical properties such as tensile strength and elastic modulus are important when
considering a new biomaterial as well, as the substrate should provide support to the cells until
local extracellular matrix is synthesized.49
1.3.1 Naturally Occurring Polymers
Natural ECM components such as collagen and fibrin are commonly used polymers for
tissue engineering. 45, 50 Modified polysaccharides such as chitosan and cellulose are also
actively studied.51 It can be inferred that given these are naturally occurring, the probability of an
immune host response is negligible. They provide a natural substrate for cell migration and
adhesion and therefore, are among the favorite group of polymers studied. Decellularized tissues
have been utilized as well, although it has shown poor repopulation in vivo.45,52 There has been
some evidence on immunogenic responses by the body to foreign collagen.53 For such cases, the
process of cross linking has been suggested with satisfactory results.54 Mechanical properties and
11

degradation rates are however, proven to be extremely difficult to control in naturally occurring
polymer scaffolds.54
1.3.2. Synthetic Polymers
Synthetic polymers are essential materials in tissue engineering due to their varied but
controllable processing characteristics. Another added advantage is the ability to design and
modify their chemical structure as per requirement, which can consequently be used to tailor
degradation rates, if needed, and mechanical properties as well.55
Since the advent of tissue engineering as an approach in biomedicine, polyester based
materials have reigned as the materials of choice. These include poly (lactic acid) (PLA)56, poly
(glycolic acid) (PGA)56, their copolymers, poly (urethane), 44 poly e-caprolactone 57 and poly
CO

(hydroxybutyrate) (PHB).

In longer culture periods, PLA degradation releases lactic acid by

products which significantly altered the pH of the region, which in turn led to tissue
inflammation and some necrosis. 59 This can be translated to all acid based polymers such as
butyric acid and glycolic acid as well. Both PGA and PLA have been used in several clinical
applications. For example, PGA has been used as a suture 60, scaffolds for cardiac tissue
engineering 4, vascular tissue engineering 61, and valvular tissue engineering 62. Similarly, PLA
has also been used in 3D tissue models and has shown slightly higher resistance to hydrolytic
degradation due to increased hydrophobicity.63
Other materials studied for vascular tissue engineering are polyurethanes. Polyurethanes
are synthesized from diols and di-isocyanates, the latter of which may potentially release toxic
degradation by-products.64 This class of synthetic materials is in wide industry use as well as in
biomedical engineering. Polyurethanes are easily compliant and show good mechanical
12

characteristics and biodegradability. 60 Not only is it possible to create a polyurethane structure
that lasts a long time in vivo to function as a permanent prosthesis, but degradation time can be
varied to produce a scaffold that only lasts a few days.60 It has been shown that medical grade
polyurethane scaffolds are also effective in maintenance of differentiated smooth muscle cell
phenotype.65
1.3.3

Biodegradable Polymers
As mentioned earlier, PLA, PGA and their copolymers have been of great interest in the

biomedical field for quite some time; this is largely attributed to their biodegradable nature. In
tissue engineering, biomedical devices such as sutures, scaffolds, drug delivery vehicles and
surgical implants are often developed to be biodegradable and to elicit minimal foreign body
response.60, 66 Of these, aliphatic polyesters such as PLA and PGA have been the most widely
investigated in the past years. Despite their degradable nature, polyesters do not possess tunable
degradation characteristics. This is largely in part due to their synthesis from one monomer
alone.

cn

In order to make them tunable for biodegradation, copolymerization of polymers or

blending is adopted which is not successful all times.60 Another concerning issue, as previously
mentioned, is the toxicity of the acidic degradation products of these polyesters; this is not
suitable in a cellular environment and therefore limiting the use for in vivo tissue engineering.
Recent renewed interest however, has been directed at addressing these issues and
concerns faced by aliphatic polyesters. A group of novel poly(ester amide)s (PEAs) comprised of
a-amino acids have been suggested for use in biomedical applications; this family of polymers
has tunable characteristics and are compliant both for hydrolytic and enzymatic degradation. ’
Their degradation products are not likely to be toxic due to their physiological origin; they have
also shown to be to prone to cleavage by enzymes such as chymotrypsin.
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Puiggali et al used

interfacial condensation to develop crystalline PEAs using amino acids glycine, L-alanine and LD,alanine.67, 69'71 A preliminary biodegradation study showed that these PEAs degrade both
hydrolytically and enzymatically and that degradation rate varied with stereospecificity.71 ’72
Katsarava and his coworkers reported a family of PEAs derived from solution
polycondensation of di-p-toluenesulfonic acid salts of alkylene diesters and di-p-nitrophenyl
esters of diacids. 73,74 These PEAs were shown to have a range of molecular weights and were
suitable for the controlled drug release and gene therapy. Recent research from the same group
developed PEA microspheres with high encapsulation efficiency that were loaded with
paclitaxel, a drug used both for the treatment of various types of cancer and cardiac restenosis.75
As there is only a handful of evidence about these PEAs for use in biomedical applications as
compared to other aliphatic biodegradable polyesters, this work attempts at developing a PEA for
vascular tissue engineering applications, which are further outlined in section 1.5.
1.4 Scaffold Fabrication Methods
There are a number of scaffold fabrication methods used for tissue engineering; the ones
outlined below are freeze drying, fibre-bonding, solvent casting/particulate leaching and finally,
electrospinning.
1.4.1 Freeze Drying
In the freeze drying method, the polymer is dissolved into a suitable solvent which is then
added to water to obtain an emulsion.66 The solvent is then removed by lyophilization under high
vacuum, thus leaving a porous substrate. The resulting constructs are foams, which have
capillary type pore structures. It is typically used for scaffolds to be fabricated from collagen,
which are usually heat sensitive.43 However, the capillary type pores that are formed are often
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irregular in size and may not be suitable for cell seeding. Recent studies however aim at
addressing this issue to obtain more uniform pore sizes by altering techniques such as freezing
rates or controlling temperatures.43
1.4.2 Fibre Bonding
In this method first developed in 1994, polyglycolic acid (PGA) fibres are immersed in a
poly (lactic acid) (PLA) solution, and the solvent is evaporated allowing the PGA fibres to
embed in the PLA. By heating beyond the melting temperatures of both polymers, the PLA melts
first, filling the voids left by the fibres, and as the PGA begins to melt, the fibres weld together.76
The PLA is then dissolved out from the composite in methylene chloride, leaving behind porous
PGA mesh, with pore sizes ranging from 30-35 pm, the largest value being around 200pm.

A

further modification proposed by this technique is combining it with freeze drying and
emulsification. After removing PLA, distilled water was added to form an emulsion. The mold
was then quenched in liquid nitrogen and freeze dried to remove water and the methylene
chloride. Combining the two methods allowed for control of pore sizes and overall porosity.76
1.4.3 Solvent Casting/ Particulate Leaching
For this method, both degradable and non-degradable polymers that are soluble in an
organic solvent of choice are employed. 64 The actual process makes use of the chosen polymer
in a solution; often chloroform or methylene chloride is used. Sieved porogens such as
ammonium chloride, sodium chloride or paraffin particles are then added to this solution and the
solution is air dried or evaporated in vacuum overnight to obtain a polymer and salt mixture.
Subsequent washing of this mixture with a second solvent, such as water or in the case of
paraffins, hexane, then leach the porogen out, leaving a highly porous polymer. 4 In order for this
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method to work effectively, the solvent dissolving the polymer must not dissolve the porogen
and the second solvent dissolving the porogen must not affect the polymer.
The pore size, interconnectivity and porosity of the scaffold is controlled by the amount
and size of the porogen that is added to the solution.

'

This property and the fact that the

method is relatively simple allow solvent casting and particulate leaching suitable for scaffold
fabrication. The technique does, however, pose some disadvantages. When the porogen is
dissolved into the polymer solution, the prevailing difference in densities of the salt and polymer
leads to a non uniform distribution.

Consequently, when the polymer-porogen mixture is

washed out after evaporation of the solvent, the uneven distribution does not allow for complete
leaching of the porogen. The final scaffold therefore usually has a small concentration of
porogen enveloped in its pores. Additionally, during solvent evaporation, the formation of a solid
layer causes the organic solvent to be trapped in the final structure. Also, the amount of time
required to completely wash the porogen out and produce the scaffold is tedious and slightly
cumbersome.78 This method generally produces irregular pores with sizes between 30-300 pm.4
1.4.4 Electrospinning
This method is another widely used approach to produce scaffolds and is effective in
producing tubular constructs in fibrous configurations, which are useful when mimicking the
extracellular matrix. Electrospinning has been known since 1902, when Cooley and Morton
produced fibres using this process.21,79 However, it was not until the mid 1990s that research in
electrospinning was applied to fabricate tissue engineering scaffolds. The significance of
electrospinning is mainly due to the potential of this method to create fibres of diameters ranging
from submicron to nanometers. A typical laboratory setup consists of a high voltage source, a
grounded collector and a syringe pump. The polymer is dissolved in a solvent; this solution is
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then forced through a needle using a syringe pump. This needle is connected to the high voltage
supply, which induces charge into the solution. When the electric potential of the surface exceeds
a certain critical value, the surface tension is overcome and the solution erupts from the end of
the needle, forming a Taylor cone.79,80 As the jet of solution erupts, it undergoes a whipping
instability, which increases the travel time as well as the total path length of the fibre to the
grounded collector; the increased time allows for maximum solvent evaporation and the path
length creates thinning of the fibre. 45, 81,82 Several configurations can be employed for the
collector, such as a stationary plate or a rotating mandrel.

’

Utilizing a stationary collector

creates a randomly oriented fibre mat, whereas a rotating mandrel provides more control and
produces an aligned fibre mat.

70 81

The versatility of scaffolds that can be produced using electrospinning serves as a
significant advantage when developing vascular tissue constructs. It also allows for enhancement
of mechanical properties such as tensile strength by manipulation of process parameters (mandrel
speed, distance from collector, etc). As mentioned previously, the geometry of the scaffold can
be influenced by the collector configuration; a rotating mandrel is used so that a tubular structure
for coronary arteries can be formed, if mats are required then the grounded collector is a flat
surface. ’

The disadvantage associated with this method is that smaller inter-fibre spacing

causes some issues with cell infiltration during cell delivery and fostering. Despite this,
10

electrospun nanofibres best mimics several ECM proteins. ’

f iî

1.5 Objectives and Rationale
There are several biomaterials that are currently being studied as scaffolds in tissue
engineering and regenerative medicine. Among these poly (ester amide)s are one of the emerging
candidates since they can be tunable in terms of their degradation rate and, also the degradation
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products may not be toxic. These properties can reduce the limitations prevalent in other
synthetic polymers that are currently used. This work focuses on developing a novel PEA for use
as scaffolds for vascular tissue engineering. To fabricate scaffolds, electrospinning is proposed to
produce fibrous constructs that could potentially mimic the structure of the natural ECM. In
addition, fibres produced by electrospinning can be controlled to very small diameters, typically
smaller than that of a cell, thereby prompting cell adhesion, proliferation and migration.
In view of the above, the objectives of this study were to:
•

Synthesize and characterize a poly (ester amide) from L-alanine, 1,8-octanediol and
sebacoyl chloride;

•

Fabricate scaffolds by electrospinning and optimize electrospinning parameters;

•

Conduct biodegradation studies under physiological conditions;

•

Assess the interaction of human coronary artery smooth muscle cells (HCASMCs) with
these electrospun scaffolds.
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CHAPTER 2
2 Materials and Methods
2.1 Materials
e-Polycaprolactone of molecular 80,000 Da was purchased from Solvay Products (Capa®
PCL, Perstorp Group, Sweden) and p-toluenesulfonic acid salt was purchased from JT Baker
(Phillipsburg, NJ). All solvents were procured from Caledon Labs (Georgetown, ON). All other
chemicals, including L-alanine were obtained from Sigma Aldrich (Milwaukee, WI) and were
used as received.
2.2 Methods
2.2.1 Monomer Synthesis
L-alanine (5.0 g, 56 mmol, equivalent to 2.2 mol),/»-toluenesulfonic acid« H2 O (11.67 g,
61 mmol, equivalent to 2.4 mol ) in 125 mL of toluene was suspended in a three-necked round
bottom flask with a stirrer and refluxed at 140°C while attached to a Dean-stark apparatus for 2
hours to remove all traces of residual water. 1, 8-octanediol (3.7 g, 26 mmol, equivalent to 1.0
mol) was subsequently added and heated in an oil bath and refluxed for a period of 40 hours. The
resulting mixture was cooled to room temperature, filtered and then recrystallized twice from 30
mL of isopropanol to provide the monomer.
'H-NMR (400 MHz, DMSO-cL) : 5 8.26 (br s, 6H, -NH3+TsO), 7.48 (d, 4H, J=8.2, Ar-H meta
to CH3)>7.12 (d, 4H, J=7.8, Ar-H ortho to CH3), 4.2-4.08 (m, 6H, -C(0)0-CH2-, -C„H), 2.29 (s,
6H, Ar- CH3), 1.64-1.57 (m, 4H, -C(0)0-CH2-C//2-), 1.38 (d, 6H, J=7.2, -C„H- CH3), 1.35-1.25
(m, 8H, C(0)0-CH2-CH2-(C/72)4-). Yield: 85%
Another monomer was synthesized in a similar manner using L-phenylalanine and 1, 4butanediol.
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'H-NMR (400 MHz, D M SO -4): 5 4.25 (br s, 6H, -NH3+TsO), 7.48 (d, 4H, J=8.39, Ai-H meta
to CH3),7.11-7.09 (d, 4H, J=7.8, Ax-Hortho to CH3), 4.2-3.95 (m, 6H, -C(0)0-CH2-, -C„H), 2.27
(s, 6H, Ar- CH3), 1.64 (m, 4H, -C(0)0-CH2-C//2-), 1.32 (d, 6H, J=1.2, -C„H- CH3), 1.33-1.29
(m, 8H, C(0)0-CH2-CH2-(C//2)4-). Yield: 85%
2.2.2 Polymer Synthesis
Interfacial polymerization was used to obtain the polymers. Sebacoyl chloride (1.20 g,
0.005 mol) in 15 mL of dichloromethane in an addition funnel was added dropwise to either of
an aqueous solution of the monomers (3.16 g for AOSe and 3.64 g for PBSe, 0.005 mol) and
sodium carbonate acting as the proton acceptor (1.06 g, 0.010 mol) until completion. The
mixture was stirred at room temperature for 12 hours and then dichloromethane and water were
extracted with a rotary evaporator at a temperature of 50°C and 100°C respectively.

The

resulting polymer was purified using Soxhlet extraction for 48 hours and dried under vacuum at
room temperature.
'H-NMR for AOSe(400 MHz, DMSO-d*): 6 6.18 (d, 2H, 5=1.21, -HH-CO-) 4.59, (m, 2H, C«H), 4.16-4.09 (m, 4H, -C(0)0-C//2-), 2.24-2.17 (m, 4H,-NH-C(0)-C//2-), 1.66-1.63 (m, 8H, C(0)0-CH2-CH2-, -NH-C(0)0-CH2-C//2.), 1.3-1.23 (m, 22H, -C„H- CH3, C(0)0-CH2.CH2.
(CH2)4-,-NH-C(0)-CH2-CH2-(CH2)4-).
‘H-NMR for PBSe(400 MHz, DMSO-d*,): 5 1.1-1.2 (Ar-H), 4.25 d, 2H, 5=1.21, -NH3+CHOO-),
4.10 (m, 4H, -C(0)0-CH2-) 3.20 (CH2-Ar), 2.25 (m, 2H, CH3-Ar), 1.65 (-COOCH2CH2), 1.20 (CH2)
Figure 1 shows the reaction scheme for the polymerization to obtain the poly(ester amide).
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Figure 1: Synthetic scheme for PEA from L-alanine, 1, 8-octanediol, sebacoyl chloride

2.3 Polymer Characterization
2.3.1 Spectroscopic Analyses
'H-NMR (400 MHz) spectra were obtained on a Varian Inova 400 spectrometer (Varian
Canada Inc., Mississauga, ON). Chemical shifts are reported in parts per million (ppm) and are
calibrated against residual solvent signals of dimethyl sulfoxide (DMSO, 8 2.5 ppm). All
coupling constants (J) are reported in Hertz (Hz). Fourier Transform Infrared (FTIR) spectra
were recorded by averaging 32 scans at a resolution of 1/cm using Bruker Vector 22
spectrophotometer.
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2.3.2 Gel Permeation Chromatography (GPC)
Gel Permeation Chromatography data was obtained using a Waters 2695 Separations
Module that was equipped with a Waters 2414 Refractive Index Detector (Waters Limited,
Mississauga, ON) and two PLgel 5pm mixed-D (300nm x 7.5mm) columns connected in series
(Varian Canada Inc., Mississauga, ON). Samples (5 mg/mL) dissolved in DMF with 10 mM
LiBr and 1 % (v/v) at 85°C was injected (100 pL) at a flow rate of 1 mL/min and calibrated
against polystyrene standards. Molecular weights are reported in g/mol.
2.3.3 Thermogravimetric Analysis (TGA) and Differential Scanning Calorimetry (DSC)
Thermogravimetric analyses were carried out on a SDT Q600 (TA Instruments, DE,
USA) under dry nitrogen at a heating rate of 20°C/min (for AOSe and polymer blends) and
10°C/min for PCL, up to 600°C. Differential scanning calorimetry was performed on a DSC
Q200 V24.2 Build 107 (Mettler-Toledo GmBH, Switzerland) at a heating rate of 10°C/min from
-50 to 200°C. All samples prepared ranged from 2 to 5 mg and glass transition temperatures
(Tgs) were obtained from the second heating cycle.
2.3.4 X-Ray Diffraction (XRD)
X-ray diffraction was carried out on a Rotaflex RTP 300RC (Rigaku, Japan) to assess the
crystallinity of the synthesized PEA and polymer blends. It was run at 107min at a step size of
0.02 and between 20 angles of 5-65° and cobalt a-radiation of 45kV and 160mA.
2.3.5 Fourier Transform-Infrared Microscopy (FT-IR)
Fourier Transform Infrared (FTER) spectra were recorded by averaging 64 scans at a
resolution of 1/cm using Vector 22 spectrophotometer (Bruker, MA, USA) to characterize peaks
of both monomer and PEA.
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2.4 Scaffold Fabrication
2.4.1 Electrospinning of PEA to form Fibrous 3D Mats
Varying concentrations of PEA in chloroform, ranging from 15%-30% w/w were
electrospun at optimized parameter values at a voltage of 13 kV, flow rate of 0.08 mL/h and
varying distances of 7, 8 and 9 cm from the collector. Varying amounts of PCL at a fixed
concentration of 8% w/w in chloroform were used as viscosity modifiers and added to each
sample. The PEA-PCL solutions were then continuously stirred in a sealed beaker under the
fume hood for 1.5 hours in order to ensure homogenous mixing. Due to this, the final
concentrations of all the samples varied from 14-21.5%, in varying compositions of PEA to PCL.
These ratios are as follows (PEA:PCL): 65-35, 70-30, 75-25, 80-20 and 82-18. After Fibres were
obtained, they were dried in a fume hood at room temperature for 24 hours and then slowly
peeled off from the aluminum foil.
2.5 Scaffold Characterization
2.5.1 Scanning Electron Microscope (SEM)
Fibre morphology of the scaffolds for each of the electrospinning condition as well as
degradation studies was visualized using SEM, (S-2600N, Hitachi, Japan). Samples were
mounted on carbon-taped aluminum stubs and gold-sputtered at 15 mA for 1.5 minutes prior to
analysis. In order to assess fibre diameter and pore size distribution, ImageJ software (NIH,
Bethesda, MD, USA) was used to obtain a sample size of 100 Fibres or 100 pores.
2.6 Degradation Study
Both qualitative and quantitative degradation studies were carried out. Due to the fact that
the PEA was not suitable for electrospinning on its own, PEA discs were used as a control. For
qualitative analysis, all other samples used were obtained by electrospinning at the specific
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concentrations as mentioned in the preceding section. Samples measuring 20mm by 20mm (n=3)
were cut, using scissors and were placed in vials containing lOmL of phosphate buffered saline
(PBS) at a pH of 7.4. All samples were incubated at 37°C for up to 28 days. Prior to SEM
analysis, samples were taken out of PBS, rinsed several times with distilled water and then dried
under vacuum at room temperature overnight.
For quantitative studies, discs were used so as to standardize the measurements
throughout the experiments. Samples used for degradation of polymer films, (PEA and PCL)
were obtained by heat pressing at 150°C and 200kPa for 2 minutes. Polymer blend films
however, were obtained by dissolving the samples in chloroform at the specific concentrations
and then by casting in a circular aluminum pan. The solvent was allowed to evaporate overnight
and then the resulting cast was heat pressed at the same conditions as above. Polymer discs of 12
mm in diameter were then punched out and were weighed prior to incubation. They were then
incubated in vials at 37°C containing 10 mL of PBS for up to 28 days. Prior to weighing,
samples were taken out of PBS, rinsed with distilled water and then dried under vacuum at room
temperature.
2.7 Cell Proliferation, Cytotoxicity and Western Blot Analyses
Samples were prepared for cell cultures by punching out heat-pressed PEA films into
small 12 mm diameter discs, and punching out electrospun polymer blend mats of varying
concentrations and electrospun PCL films at 8%w/w. All samples were affixed to coverslips
using silicone grease and sterilized by immersion in ethanol for 30 minutes. The films were then
washed with PBS and transferred to a 24-well cell culture plate (BD Biosciences, San Jose, CA)
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and incubated in lmL of culture medium at 37°C overnight. Following this, cell seeding was
carried out as follows:
Human coronary artery smooth muscle cells (HCASMCs; Cambrex Biosciences,
Walkersville, MD) between passage 6 and 10 were used to evaluate the attachment and
spreading of vascular cells on PEA films, PEA-PCL electrospun mats and control PCL mats.
HCASMCs were cultured in SmGM-2 (smooth muscle growth medium-2 with Bullet Kit;
Cambrex) supplemented with 1% penicillin/streptomycin solution (P/S). Cultures were
maintained in a humidified incubator at 37°C and 5% CO2 . HCASMCs were seeded onto films at
an initial cell density of approximately 104cells/cm2and cultured for 4 and 7 days before fixation
and immunostaining. Following culture time, cells were fixed at 4°C for overnight in 4%
paraformaldehyde (EMD Chemicals, Gibbstown, NJ) in divalent cation-free PBS and
permeabilized with 0.5% Triton X-100 in PBS. HCASMCs were incubated for 1 hour at ambient
temperature in 1% BSA/PBS containing Alexa Fluor® 568 phalloidin (Invitrogen, Eugene, OR;
1:50 dilution). Hoechst 33342 (10 pg/mL; Sigma-Aldrich) dissolved in PBS was used to label
nuclei. Cover-slips were mounted on glass slides in Vectashield (Vector Laboratories,
Burlington, ON) and then sealed with nail enamel. Imaging of samples was carried out on a
Leica DM-IRB fluorescence microscope equipped with epifluorescence and the appropriate
filters (Leica, Canada).
For cytotoxicity, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay was carried out following the manufacturer’s protocol (Vybrant®, Invitrogen, Burlington,
ON, Canada). Cells were seeded onto electrospun PEA-PCL mats as well as PCL and PEA
control films. The initial cell density was 6*104 cells/scaffold in 96-well tissue culture plates
which were then cultured for 4 days. An MTT solution was added to each well to make the final
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concentration 1.10 mM and then incubated at 37°C. After removal of the supernatant, dimethyl
sulphoxide (DMSO) was added; absorbance was recorded at 550 nm by a plate reader and
quantified using a standard curve. Negative control experiments were carried out by adding MTT
to the culture medium only.
Finally, Western blot analysis was used for elastin expression and HCASMC phenotypic
marker proteins. Following specified culture times, cells were washed three times at specific
with ice-cold PBS and whole cell lysates were obtained by harvesting cells in 100 pi of sodium
dedecylsulphate (SDS) electrophoresis sample buffer containing 5% (v/v) p-mercaptoethanol.
Lysates were sonicated and then followed by microcentrifugion. Protein concentrations were
determined by 660 nm Protein Assay (Thermo Scientific, Ottawa, Canada). Protein samples (80
pg for evaluating elastin expression were separated by 10% SDS-PAGE and subsequently
transferred at 90 V for 1 hour at 4°C to nitrocellulose membrane in a Tris-glycine buffer. The
membranes were blocked by the utilization of 5% nonfat dry milk in PBS and were incubated
overnight at 4°C with primary antibodies (monoclonal mouse anti-elastin at 1:200; anti-SM-aactin and anti-GAPDH at 1:2000; all others at 1:1000). Transfer efficiency and homogeneous
loading was verified by Ponceau red stain. The blots were then labeled with Alexa 680- and
IRDye 800-conjugated secondary antibody (Invitrogen, Burlington, ON, Canada), and labeled
proteins were visualized by the Odyssey system (LI-COR Biosciences, Lincoln, NE). Protein
bands on the Western blots were quantified using Gel-Pro Analyzer (Version 4.0) software and
the results were normalized as the ratio of elastin, SM-a-actin, and calponin to GAPDH.
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CHAPTER 3
3 Results and Discussion
3.1 Polymer Synthesis and Characterization
Initially, synthesis of another poly (ester amide) consisting of L-phenylalanine (P), 1,4butanediol (B) and sebacoyl chloride (Se) was attempted. Although this polymer named PBSe
was successfully synthesized, it did not dissolve in a variety of organic solvents for
electrospinning and hence was not considered further. Due to this, efforts were made to
synthesize another poly (ester amide) from L-alanine (A), l,8-octanediol(0) and sebacoyl
chloride (Se). It was obtained by interfacial polymerization following the scheme outlined in
Figure 1. L-alanine was chosen because of its short side chain which subsequently contributes to
crystallinity. 1, 8-octanediol was chosen due to its long carbon chain, which in turn provides
flexibility.
Interfacial polymerization was chosen due to several reasons. Firstly, restrictions on
purity and stoichiometry are not as rigid and, a common solvent for both monomers is not
necessary. This allows for the formation of high molecular weight polymers on the interface of
the two solutions. Secondly, because the reaction was carried out at a low temperature, high rates
of reaction overcome any potential for side reactions to occur. This way, linear polymers of high
molecular weights can be synthesized. Polymerization times were also significantly reduced
compared with solution polymerization times.84
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3.1.1

Structural Analysis
The structures of the polymers were confirmed by 1H-NMR and FT-IR spectra. Figures 2

and 3 show the 'H-NMR spectra for polymers PBSe and AOSe respectively.

Figure 2:*H-NMR spectra of PEA from L-phenylalanine, 1,4-butanediol and sebacoyl
chloride (PBSe)
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Structure is confirmed by peaks obtained and are labelled from 1-9. Due to the aliphatic nature of
L-alanine, no aromatic peak is observed at 7ppm as compared to Figure 2.

Chemical Shift (ppm)

Figure 3: H-NMR spectra of PEA from L-alanine, 1,8-octanediol and sebacoyl chloride
(AOSe)

The 'H-NMR spectra confirms the structure of both PBSe and AOSe. In the case of the
former, the aromatic groups present in L-phenylalanine are shown at a chemical shift of 7.2 ppm
(1-5) and the amino group N-H at 6.01 ppm and 4.5 ppm (7 and 8). The reason that these groups
are further downfield than the rest is due to the electron withdrawing nature of these bulky
groups, where the electron cloud that normally surrounds the ’H are pulled away from the
nucleus, thus creating a de-shielding effect. De-shielding causes the hydrogen nucleus of these
molecules to resonate at lower field intensity. Conversely, electron donating atoms such as the
carbons present in the methyl groups shield the nuclei, thus creating a tightly bound electron
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cloud and therefore presenting an upfield position on the spectra, indicated by numbers 10 and
12 at 1.5 ppm and 13 at 1.25 ppm. Splitting occurs at 9, at 4ppm, due to the presence of two
different magnetic environments on the hydrogen nuclei in that environment. This means that at
any given time, as a result of their different states, the hydrogen atoms attached to the oxygen
and to the carbon, influence each other due to their position of being within three bonds of each
other. Consequently, they cause slightly upfield and downfield shifts: A doublet forms as there is
approximately a 50% chance that the hydrogen atoms will be in one of the two states.
Similarly, the NMR spectrum for AOSe confirms the synthesis of the compound. The
amino group is shown at 6.2 ppm (3) and 4.5ppm (2). Very shielded 'H nuclei are shown further
upfield at 1.25 ppm (1, 6, and 9) and 1.5 ppm (5 and 8).

AOSe polymer was further

characterized by Fourier Transform Infrared Spectroscopy, as shown in Figure 4.
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Wavelength ( c m 1)
Figure 4: FT-IR of degradable AOSe PEA synthesized by interfacial polymerization
Note: Peak at 3300cm'1 shows primary amide, 2922cm"1 shows amide B. At 1730cm'1 is the
carbonyl ester stretch and at 1640cm"1, N-C bond amide as Amide I. The Amide II region is the
asymmetric N-C bond at 1540cm'1.
For FT-IR absorption, vibrations must result in a bond dipole moment in order for it to be
recorded in the fingerprint region. Asymmetric bonds are clearly displayed in the spectra shown
above. Bond stretching involves the largest change in energy and thus can be observed in the
higher frequency regions between 3500 and 1500 cm'1. Beyond this region, between 1500 and
400 cm'1, vibrations generally constitute a combination of bending, stretching and rotating, and
attributes to being the fingerprint region of the molecule. A strong primary amide absorption can
be seen at 3300 cm'1 and can be classified as a sharp N-H stretch, as depicted in Figure 4. At
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2922 cm'1, a C-H2 stretch is observed because of the aliphatic region of the amino acid; this is
the intermolecular hydrogen-bonded amide and is marked as Amide B. The peak at 1730cm'1
corresponds to the ester carbonyl stretch. Furthermore, at 1640 cm"1, a peak showing symmetric
N-C bond amide can be seen, which is shown as Amide I. The Amide II region corresponds to
the asymmetric N-C bond at 1540 cm'1.
Gel Permeation Chromatography was used to determine molecular weight and
polydispersity index of the polymer. Molecular weight is an extremely useful representation of
the polymer’s physical characteristics. A high molecular weight polymer, for example, is one
that has optimal mechanical properties and a fairly high transition temperature. Given that
polymers generally have a varied distribution of molecular weights, GPC is a useful method to
assess the average molecular weight; it separates the molecules based on hydrodynamic volume
and is therefore plotted as a function of elution volume. Figure 5 shows the GPC trace for AOSe
PEA from which an average molecular weight of 32,000 g/mol and a polydispersity index of
1.56 were obtained. The yield for the PEA ranged from 80-85%.
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Figure 5: GPC trace of AOSe synthesised by interfacial polymerization

3.1.2

Thermal Analysis
In order to determine the glass transition temperature (Tg), DSC experiments were carried

out. As it can be seen in Figure 6, the Tg is approximately 13.5°C. This relatively low
temperature is probably due to the long carbon chains of 1,8-octanediol the ten carbon chain of
sebacoyl chloride. In addition, there are no aromatic groups that allow for domination of
transition temperature. There were no melting transitions during the second heating cycle.
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Temperature (°C)

Figure 6: DSC trace of AOSe, showing the glass transition temperature to be 13.5°C
With regard to PCL, it has been confirmed from literature that the glass transition
temperature is -60°C and the melting temperature is around 60°C.

It is also semi-crystalline

due to its nature to pack very tightly. Polymer blends ranging from PEA: PCL ratios of 65:35 to
82:18 were prepared by heat-pressing into discs to analyze thermal property trends. The resulting
curves are shown in Figure 7.
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Figure 7: DSC traces of PEA-PCL blends at different ratios
As such, the polymer blends seem to show Tg values of both PEA as well as PCL. Tg
values of PEA can be clearly seen on the 82PEA-18PCL curve, whereas it is not as apparent in
the others. It is worth to notice that as PEA concentration increases, PCL properties may
dominate. Due to a small increase in free volume, Tg values may reduce slightly. Glass transition
temperatures of PCL seem to fluctuate between the ranges of -57 and -63 °C throughout the
different ratios of polymer blends. Based on packing densities and existing knowledge of PCL, it
can be stated that the more percentage of PCL present in the polymer blend, the greater the value
of the melting temperature, Tm. This can be attributed to the fact that more energy is required to
overcome the cohesive forces, thereby increasing the overall melting temperature as well. For
these blends, it can be seen from Figure 7 that they fluctuate between 52 and 63°C and in most
cases, follow the above mentioned trend. However, only further in-depth studies about the
thermal character of these blends can shed light on whether the curves are indeed following a
trend or if it is simply a matter of statistical fluctuations. Polymer blends showed thermal
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properties of both PEA as well as PCL. Although not very clear, Tg values are present both
around the -60°C region as well as 13.5°C. With respect to melting temperatures, range of
values between 52°C and 63 °C exhibit transitions for PCL.
Thermogravimetric analyses of the PEA and PEA-PCL blends are shown in Figure 8.
Accordingly, it can be seen that blends as well as controls are all thermally stable, owing to
strong packing and presence of aliphatic side chains. Derivative peaks to determine onset
decomposition temperatures were found to be around 285°C for all polymer blends, as well as
the controls (See Appendix A). The difference in the shape of the curves between the blends and
control PEA can be attributed once again to the difference in packing structures between the
polymers. As PCL packs tightly, its presence in the blend may dominate its thermal
characteristics although the blends seem to essentially exhibit aspects of both PEA as well as
PCL.

36

100

-

80 -

O

60 H

#

40

20

-

65PEA-35PEA
70PEA-30PCL
75PEA-25PCL
80PEA-20PCL
82PEA-18PCL
Control P CL
Control PEA

— i—

100

200

300

T e m p e ra tu re (°C)

Figure 8: TGA traces of polymer blends and controls. Blends as well as polymer controls
can be seen to be thermally stable. Onset decomposition temperature is around 285°C for
all curves.

3.1.3 XRD Analysis
X-ray diffraction was carried out on both polymers as well as one polymer blend
(70PEA-30PCL) and results are shown in Figure 9. From the curves obtained, it can be seen that
all three samples are semi-crystalline.
PCL diffraction at 20 values of 21.7° and 23.9° indicate peak maxima corresponding to a
¿/-spacing of 0.415 nm and 0.384 nm respectively, which seems consistent with literature.

PEA

showed strong diffraction patterns at an angle 20 of 21.2°, which can be converted to a d-spacing
of 0.412 nm. It is interesting to compare these values to the spectra of the polymer blend. The
polymer blend, 70PEA-30PCL, shows strong diffractions at three different points and indicates
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semi-crystallinity as well. Although the diffraction angles of 21.6° and 23.6° seem to mirror PCL
maxima, the PEA peak has been shifted to 25.4° (d-spacing = 0.287 nm). Also, electrospun
fibres of crystalline polymers usually are less crystalline than pure polymer powders due to
o s

solvent evaporation; as a result, the polymer blend peaks are not as pronounced.

This can be

explained by the stretching of fibres during electrospinning as well as the evaporation of the
solvent, which both occur so fast that the polymer chains are not allowed sufficient time to
crystallize completely.

oz

In addition, it can be seen that all the minor peaks associated with both

the polymer controls are depicted in the polymer blend, namely at diffraction angles of 29.2°,
35.1° and 39.6°. Once again, the peaks from PEA seem to have shifted slightly when compared
to their position on the polymer blend spectra. This can be attributed to the domination of PCL
packing over PEA, and therefore exhibits no shifts in peaks.

20

Figure 9: XRD Spectra of PEA, PCL and 70PEA-30PCL. Peaks as reported in literature
can be observed for PCL at 21.7° and 23.9°.86 PEA maximum occurs at 20 value of 21.2°.
70PEA-30PCL polymer blend shows diffraction peaks at 21.6°, 23.6° and 25.4°.
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3.2 Electrospinning
Despite its difficulty to dissolve in many organic solvents, attempts to electrospin PBSe
using dimethylsulfoxide (DMSO) as a solvent was carried out. However, this was not pursued
further due to the fact that DMSO’s high boiling point meant that the solvent did not completely
evaporate upon reaching the collector and, therefore, the polymer solution re-dissolved after
reaching the collector. Even after drying the samples in vacuum overnight, no fibres were
observed. PBSe in concentrations greater than 5% w/w was not soluble in DMSO or any other
organic solvent and, hence, limited its utility.
PEA based on AOSe was then successfully synthesized as it is a readily soluble in
chloroform up to 35% w/w. At this concentration, the solution was not however viscous enough
for electrospinning. In order to increase the viscosity such that it can be electrospun, PCL was
added as a viscosity modifier. PCL was chosen due to its commercial availability,
biodegradability and previously published results showing its application in the field of
biomedical engineering.39 The amount of PCL added to the PEA was varied from 18% to 35%
PCL. A minimum of 18% was required to electrospin the solution while the upper limit was set
in order to limit the influence of PCL on the electrospun fibres.
Sample nomenclature is based on the weight percentage of the PEA and PCL used in the
preparation. For example, 65PEA-35PCL means an electrospun fibre mat from 65 wt% PEA and
35 wt% PCL. Accordingly, five compositions namely, 65PEA-35PCL, 70PEA-30PCL, 75PEA25PCL, 80PEA-20PCL and 82PEA-18PCL were prepared and electrospun. Figure 10 shows
representative SEM micrographs of electrospun mat spun at different solution concentration and
needle-to-collector distances. It can be seen that the fibres are randomly oriented and are
reasonably uniform in sizes with no beading effect.
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Figure 10: SEM images of different electrospun mats at different magnifications,
concentrations and distances to collector. Fibres were electrospun at 13kV and flow rate of
0.08mL/h. 70PEA-30PCL (14%w/w) at 8cm (A) and 14cm ;(B) 82PEA-18PCL (21.5%w/w)
at 8cm (C) and 14cm (D)

3.2.1

Electrospinning Parameters
There are several parameters governing the process of electrospinning. These are flow

rate of the solution through the needle, voltage, polymer concentration, distance to collector and
solution conductivity. Typically, most of these parameters are kept constant while some are
varied to achieve the optimum results. For this study, two parameters namely, the polymer
concentration and the distance to collector, were studied in depth. SEM was used to characterize
the electrospun mats and ImageJ software was used to measure fibre diameters at different
concentrations, ratios and distances; pore size distributions were also studied for specific
concentrations.
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3.2.2

Effect of Polymer Concentration on Morphology and Fibre Diameter
In this study, the effect of concentration on fibre diameter was studied in two ways. Due

to the experimental setup for each polymer blend, both solution concentration (namely, 14%w/w
to 21.5%w/w), and PEA: PCL ratio are changing thus each parameter had to be studied
separately. A panel of images presented in Figure 11 demonstrates the effects of both
concentration and varying ratios of polymer blend on fibre orientation and morphology. It can be
seen that the fibres are oriented randomly in a criss-crossing grid-like pattern. This orientation is
desirable, as it mimics the actual physiological structure of the extracellular matrix and could
prove ideal for in vitro tissue engineering.

Figure 11: SEM images of electrospun mats at varying concentrations and compositions.
Electrospun at 8cm, 13kV and flow rate 0.08mL/h. A) 70PEA-30PCL, 14% w/w; B)
75PEA-25PCL , 16.5% w/w; C) 80PEA-20PCL, 19% w/w; D) 82PEA-18PCL , 21.5% w/w.
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In order to systematically study the underlying parameter affecting changing fibre
diameter, the role of the polymer ratios was studied. This was accomplished by keeping the final
solution concentration constant at 14%w/w and by manipulating the polymer composition at
70PEA-30PCL, 75PEA-25PCL, 80PEA-20PCL and 82PEA-18PCL. Pure PCL was used as a
control. As mentioned earlier, PEA could not be electrospun on its own, as a result, only the
presence of one control was made possible. These set of experiments were also conducted for
another concentration namely, 19%w/w. Figure 12 demonstrates the fibre distribution for
different polymer blends at 14% concentration whereas Figure 13 presents the effect of varying
polymer composition on the resulting fibre diameter.

Fibre Diameter,

Fibre Diameter, jim

Figure 12: Frequency distribution of electrospun fibre diameter showing the effect of
polymer blend ratios at a fixed concentration of 14%w/w. The voltage was 13kV and the
distance to collector was 8cm.
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Figure 13: Fibre diameter for different polymer blend ratios at solution concentration of
14%w/w. Solid lines indicate that data sets are not significantly different from each other
at 95% confidence level.
It can be seen from Figure 13 that at 14% concentration, the fibre diameter increases slightly
with increasing PEA amount. 70PEA-30PCL showed average fibre diameter of 0.39±0.08 pm
and 82PEA-18PCL increased up to 0.43±0.06 pm. The post-hoc Tukey test separated the four
polymer blends into three groups. The fibre diameter of 82PEA-18PCL was significantly higher
than the polymer blends containing 70% and 75% PEA at p<0.05. A similar study was
performed for polymer blends at a fixed solution concentration of 19% w/w. The data shown in
Figure 14 is similar to results presented in Figure 13. The increase in PEA composition only
slightly increased fibre diameter. 70PEA-30PCL showed average fibre size of 0.49±0.09 pm and
82PEA-18PCL was calculated to be 0.55± 0.11 pm. The post-hoc Tukey test separated the four
polymer blends into two groups. The fibre diameter of 82PEA-18PCL was significantly higher
than the polymer blends containing 70 and 75 PEA at p<0.05. Therefore, it can be effectively
concluded that fibre diameter is not affected by the composition of the polymer blends at
constant concentration,
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Figure 14: Fibre diameter for different polymer blends at solution concentration of
19%w/w. Solid lines indicate that data sets are not significantly different from each other
at 95% confidence level.
The effect of solution concentration on fibre diameters is presented in Figures 15 and 16. Figure
15 shows the frequency distribution and Gaussian curve fit for each concentration. Figure 16
demonstrates the relationships between increasing concentrations in the range of 14%w/w to
21.5%w/w and resulting fibre diameter. It can be seen that concentration does in fact, have an
effect on fibre diameter where an increase in solution concentration increased the fibre diameter.
Average fibre size for 70PEA-30PCL was calculated to be 0.41±0.13 pm and 82PEA-18PCL
showed fibre diameters of 0.81±0.39 pm. The post-hoc comparative Tukey test separated five
different concentrations into four significant groups at p<0.05. It can be inferred from Figure 16
that the trend is consistent with literature. 79,81,83
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Figure 15: Frequency distribution of fibre diameters of varying concentrations

Increase in fibre size can generally be attributed to the fact that as solution viscosity increases,
the amounts of polymer present in the solution also increases, thus forming a thicker jet before
deposited at the collector. However, the data also shows that the standard deviation of the fibre
diameter significantly increases with increasing concentration. This is evidence that there is in
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fact, an optimal concentration for every electrospun polymer system. As viscosity increases, it
also affects solution conductivity, which in turn might cause more randomized deposition of
fibres, giving rise to fibres of less uniform diameters. Conversely, at extremely low
concentrations, it is more common to see the presence of bead formation as increased surface
tension causes droplets to erupt at a rapid speed from the tip of a needle, instead of a steady jet of
fibres forming at the Taylor cone. Frequency distributions in Figure 15 show that distribution of
fibre sizes did increase with increase in concentration. Given the narrow distribution of fibre
sizes at 70PEA-30PCL for an average fibre size of 0.41 pm, this solution concentration is
possibly the most optimal value for experiments throughout the course of the project. This
concentration was also selected for use in cell studies.
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Figure 16: Fibre diameter for different solution concentrations. Solid line indicates that
data is not statistically significant at 95% confidence level.
The effect of viscosity on the electrospun fibre size has been studied extensively and has
been demonstrated to be a significant variable. Typically, at low concentrations, a phenomenon
known as beading occurs due to increased surface tension at the tip of the needle.
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Increasing solution concentration yields more uniform fibres with fewer beads; however,
this is only up to a certain viscosity. If this value is too high, i.e, the solution concentration was
raised beyond the optimum range, the droplet dried out at the tip before a steady jet of fibres
01

on

could be formed. ’ ’

oo

In the extreme case where the viscosity is too high, electrospinning is

not possible as the solution will not be able to move through the needle even if the flow rate is
significantly increased. There seems to be a direct correlation between intrinsic viscosity [r|],
concentration (c), and final fibre size for a particular polymer solution system. These correlations
are highly system-dependent rather than universal. For example, for electrospinning poly(vinyl
alcohol) (PVA) [r|]c > 5 was reported to be essential. ’

On the other hand, [r|]c value higher

than 10 was needed for a system consisting of poly(ethylene terephthalate) (PET).90 Overall, it
can be concluded that increasing solution concentration within an optimum range results in the
increase in fibre diameter. This range is obviously varied throughout different polymer systems.
In addition to the effect of solution concentration and fibre diameter, its effect on pore
sizes were also analyzed. Pore size is an important feature for scaffolds to improve cell
attachment, infiltration and proliferation. Using sample sizes of 100, pore sizes were measured
using ImageJ for at each concentration, from 14% w/w to 21.5% w/w. Figures 17 and 18 show
the pore size distributions for different polymer blends with a fitted Gaussian curve at varying
concentrations as well as the average pore sizes respectively. It can be inferred from the figures
that pore size is dependent on fibre diameter and consequently, on polymer solution
concentration. With an increase in fibre diameter, pore size also increased. An obvious
conclusion that can be made is that increasing fibre diameters and pore size would consequently
result in a decrease in pore areas of the electrospun mat. Figure 18 shows that the average pore
size depended on the polymer ratio used. Control PCL mats showed significantly smaller pores
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than the PEA-PCL blends under otherwise identical electrospinning conditions. Figure 17 shows
that the average pore size increased from 8.01±1.29 pm for 70PEA-30PCL (14% w/w) to
20.92±2.84 pm for 82PEA-18PCL (21.5% w/w). The post hoc Tukey multiple comparative test
separated the five polymer systems displayed in Figure 18 into five significant groups at p<0.05.

Pore size, um

Pore size, fim

Pore size, nm

Figure 17: Frequency distribution of pore sizes showing the effect of varying
concentrations for PEA-PCL blends.
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It can, therefore, be concluded that solution concentration is an important parameter in
the electrospinning process since the two polymer ratios did not significantly affect the fibre
diameter. It was shown that polymer concentration was in fact responsible for the increase in
fibre diameter, due to the formation of a thicker jet at the Taylor cone. In addition, pore size is
directly related to fibre diameter; increasing fibre size leads to an increase in pore size. However,
pore size could also be related to the composition of the polymer blend; the PCL control did not
seem to fit the trend shown by the PEA-PCL polymer blends.
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Figure 18: Pore sizes of PEA-PCL blends at different compositions and concentrations

3.2.3

Effect of Distance to Collector on Morphology and Fibre Diameter
The distance from the tip of the needle to the collector is important in manipulating the

diameter of the fibres. Typically, distance has an inverse relationship with fibre diameter. It has
been shown that with increasing distance, a decrease in fibre diameter was observed.80,81,91 This
is mainly due to the fact that as distance is increased, the fibres are allowed to stretch out more
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before they are deposited on the collector. This ensures a uniform network of fibres that allows
for smaller diameters.
However, as in the case of solution concentration, fibre diameters are affected by distance
for a specific range and for a defined set of polymer systems. It has been reported in various
studies that a minimum distance is needed for every electrospun scaffold in order to obtained
dried fibres. 79’81,83 At distances either too close or too far, beading was observed. To study the
effect of distance, four distances, namely 8cm, 10cm, 12cm and 14cm from the collector were
chosen. Other parameters were kept constant and samples were spun at 13kV, 0.08mL/h at 14%
concentration. Figure 19 shows SEM images that illustrate the morphology and orientation of
fibres for 70PEA-30PCL. It can be seen that fibre morphology remained the same despite the
increasing distances and similar grid pattern configurations were formed.

50

Figure 19: : SEM images of 70PEA-30PCL mats electrospun at 0.08mL/h and 13kV (A)
8cm (B) 10cm (C) 12cm and (D) 14cm (E) beading at 12cm and (F) beading at 14cm

To quantify the effect of distance, diameters of fibres (n=100) were measured at the four
different distances. Frequency distribution plots and a bar diagram showing the relationship
between fibre diameter and distance from the collector are displayed in Figures 20 and 21
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respectively. The general trend seems to be consistent with literature,81,91 and fibre diameter is
shown to decrease with increasing distance up to a certain point. Between 8 cm and 10 cm, the
average fibre diameter decreased from 0.41± 0.13 pm to 0.37±0.09 pm then increased beyond
10cm reaching 0.47±0.09 pm at 14cm, showing that the optimal distance is probably from about
6-10cm away from the collector. In addition, at 12 and 14 cm, a lot of beading was observed as
well as the jets drying out before they had reached the collector, as depicted in Figures 19E and
19F (indicated by arrows). This in turn led to clogging of fibres at the needle tip at the time of
the experiment.
As shown in Fig 20 by the frequency distributions, Gaussian distribution is smooth and
unvaried at 8 cm and 10 cm as compared to the other two distances. Specifically, at a distance of
10cm, average diameter is the lowest with a lower standard deviation when compared to the
other distributions. From Figure 21, the post-hoc multicomparative Tukey tests separated the
four distances to the collector into three significant groups at p<0.05. The fibre diameters at 12
cm and 14 cm were not significantly different at p>0.05.
Overall, the distance from the collector produced some significant results with respect to
average fibre diameter. Due to added stretching of the fibres between the needle tip and
collector, lower fibre diameters are deposited on the collector. However, this study also showed
that this holds true only for a certain range of values, after which beading, clogging and
increased fibre diameter were all observed.
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Figure 20: Frequency distribution of fibre diameters at varying distances from collector

Fibre Diameter, ¿im

Figure 21: Average fibre diameter at different distances from the collector .Solid line
indicates data sets are not statistically significant at a 95% confidence level.
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3.3

Degradation Study
In order to determine how well the PEA scaffolds would hold up under physiological

conditions and culture medium, a series of degradation studies were carried out. For qualitative
degradation, it was necessary to evaluate the mechanism of degradation the polymer undergoes.
Therefore, the electrospun mats of the polymer blends and control PCL were degraded in PBS.
However, with regard to quantitative degradation, it was necessary to include both PEA as well
as PCL controls for an effective analysis prior to cell culture studies. Therefore, all samples, that
is, the PEA and PCL controls as well as all the polymer blends in ratios of 65PEA-35PCL,
70PEA-30PCL, 75PEA-25PCL, 80PEA-20PCL and 82PEA-18PCL were allowed to degrade.
All results were processed at the end of 7, 14 and 28 days.
3.3.1 Qualitative Degradation of PEA
Figure 22 shows SEM images of electrospun polymer blend mats in PBS after 1, 2 and 4
weeks of degradation. Three different concentrations are shown, 65PEA-35PCL, 70PEA-30PCL
and 82PEA-18PCL. Fibre degradation shows characteristics of fibre fusing, where adjacent
fibres combined to form a planar film-like appearance. The degradation rate of PCL has been
studied and was found to be extremely slow; it is usually about 2 years before a scaffold
completely disintegrates.92 Due to decreasing amounts of PCL and increasing quantities of PEA,
it can be seen that degradation is heightened between polymer blend of 65PEA-35PCL and
82PEA-18PCL, except in week one. It was expected that scaffolds made of 82PEA-18PCL will
degrade faster than 65PEA-35PCL due to the higher PEA content of the former. Fibre meshing
and fusing increased as the degradation time increased and these can be visualized in the SEM
images in Figure 22.
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Figure 22: SEM images of electrospun mats at varying concentrations in PBS after 1, 2 and
4 weeks. (A-C) 65PEA-35PCL (D-E) 70PEA-30PCL and (G-I) 82PEA-18PCL

3.3.2 Quantitative Degradation of PEA
Mass loss was used to assess degradation rates in the discs over a time period of 4 weeks.
Discs were weighed at the beginning of the experiments and thereafter at each time period,
following an overnight drying in a vacuum oven at room temperature. Two separate analyses
were computed: (1) the percentage of mass remaining of the discs with respect to degradation
time in PBS and (2) the percentage of mass remaining of the discs with respect to PEA
composition, over the course of 1, 2 and 4 weeks. It can be deduced from Figure 23 that PEA
degrades steadily over time.
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Figure 23: Percentage of mass remaining of all polymer blend discs and controls after a
period of 1, 2 and 4 weeks
It is interesting to note that while PCL barely degrades over the span of a month, the PEA
control has considerably lost its mass, and only 71% is remaining at the end of the study. If this
rate of degradation continues, it will take around 10-12 weeks for complete degradation. Another
key trend that can be seen from these curves is that mass loss significantly increased with the
increase in quantity of PEA. For example, 65PEA-35PCL shows the least mass loss due to its
high percentage of PCL. Although there is not much difference between the degradation rates of
the 70PEA-30PCL and 75PEA-25PCL blends, the other concentrations show a steady loss in
mass over 4 weeks. Overall, as the amount of PCL was increased, the rate of degradation
decreased. This is to be expected given the difference in degradation profiles between the two
polymers. It must be noted that although these are discs, the actual scaffolds designed for this
study were fabricated by electrospinning. Given the 3-D structure and porous and pliable nature
of the electrospun mats, degradation rates would increase significantly for all the polymer
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blends. A short time degradation profile such as the one exhibited by PEA is ideal for vascular
tissue engineering applications as the construct will degrade since the cells proliferate and
migrate around the new tissue.
Analysis of degradation rates with respect to composition also confirmed the abovementioned results. Figure 24 indicates that over a time period of 4 weeks, the discs with a higher
ratio of PEA degraded the fastest, whereas PCL and high PCL ratios (such as 65PEA-35PCL)
degraded much slower. At the end of 28 days, this polymer blend had only lost 8.2% of its
original mass. This value, when compared to the disc containing PEA-PCL ratios of 82-18,
which had degraded 23% of its original mass, is significantly lower.
Quantitative degradation shed new insight on PEA’s viability as a tissue engineering
scaffold material. A prime candidate for tissue engineering is its ability to degrade while cells
attach and infiltrate the scaffold to form new tissue; the profiles exhibited by PEA and all of the
polymer blends show promising results for use in cardiovascular constructs.

Composition of PEA in blend (%)

Figure 24: Percentage of mass remaining with respect to PEA concentration of polymer
blend discs and controls, at time periods 1, 2 and 4 weeks.
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Finally, in order to gain understanding on the mechanism of degradation, GPC was
utilized to measure molecular weights of degraded and undegraded polymer. 82PEA-18PCL was
chosen as it degraded the fastest of all the polymer blend discs and therefore would be most
indicative of molecular weight loss, if any. Figure 25 presents GPC overlays for different time
points over the course of 2 weeks to assess mechanism of degradation. As it can be seen,
molecular weights stay more or less the same through the 14 days, indicating surface erosion
type degradation mechanisms. Molecular weights were measured after 2 hours of incubation in
PBS as well; this was carried out in order to eliminate instantaneous leaching that are sometimes
prevalent in biodegradable polymers.
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Figure 25: GPC data of 82PEA-18PCL discs at different points during degradation, namely
after 1 and 2 weeks.
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All the data obtained in the degradation study showed a steady degradation profile
without loss of overall molecular weight. This indicates a resilient yet biodegradable polymer
that could serve well as a potential scaffold material for vascular tissue engineering.
3.4 Vascular Smooth Muscle Cell Culture Studies
The two critical components in tissue engineering are the cells and the scaffold to which
cells can attach and grow.93 Porous scaffolds, which mimic the natural extracellular matrix, are
required for 3-D growth of cells to form in vitro tissue engineered constructs. This, in turn,
requires that scaffolds should be non-cytotoxic and should promote signaling pathways that
influence key cell function such as migration, proliferation, and differentiation. In view of these,
it would be important to test the current electrospun scaffolds for cytotoxicity and maintenance
of the differentiated cell phenotype. In order to evaluate vascular smooth muscle cell (VSMC)
interactions with the current scaffolds, cell culture studies were carried out on a control pure
PEA disc, control pure PCL, electrospun mat and a polymer blend mat in the ratio of 70PEA30PCL. The pure PEA could not be electrospun by its own right so only discs were prepared by
heat pressing. The two fibre mats were chosen specifically because the average fibre diameter of
0.41 ±0.13 pm was similar to pure PCL fibre diameter, which was around 0.37±0.061 pm. For
cytotoxicity, MTT assay provides a simple method for the determination of cell number using
standard microplate absorbance readers. This assay is based on the reduction of the yellow
tétrazolium salt (MTT) to purple formazan crystal by metabolically active cells.94 This reduction
takes place only when mitochondrial reductase enzymes are active, and therefore conversion can
be directly related to the number of viable (living) cells. The formazan is then solubilised, and
the concentration determined by optical density at 570 nm. The result is a sensitive assay with a
colorimetric signal proportional to the cell number.
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Figure 26 shows the cytotoxicity data obtained following 4 days and 7 days of culture. At
day four, there was no statistical significance between the PEA fibre mat and the pure PCL fibre
mat which was used as a control. However, at day seven, cell viability on the 70PEA-30PCL mat
was statistically significant suggesting that PEA scaffolds provided a better microenvironment
for seeded vascular smooth muscle cells. Between these two samples, there was no difference in
the fibre diameter; overruling this to be a factor for the observed cell viability difference. As
discussed earlier, pure PCL did not degrade during 7 days incubation whereas 70PEA-30PCL
has lost 5% of the initial mass following 7 days of incubation in PBS. Based on this, pure PCL
could have been a better scaffold for cell vitality, but this did not seem to be the case. Although
the culture time is short and, long-term culture needs to be done, the results indicate the
degradation product was not affecting cell viability.

Figure 26: Human coronary artery smooth muscle cell viability on PEA and PCL
electrospun fibres. Scaffolds were seeded with a cell density of 6 x 104 cells/scaffold and
cultured for 4 and 7 days before MTT treatment. Data are mean±SD for experiments
conducted in triplicate. One way ANOVA and post-hoc Tukey comparative tests were used.
Solid line coupled with * indicates statistical significance at 95% confidence interval.
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Morphologically, HCASMCs were seen well-spread on all surfaces with abundant Factin as shown in Figure 27. Comparing these images, it appears that cells seeded on the 3-D
fibres (both pure PCL and 70PEA-30PCL) were denser than cells seeded on the pure PEA disc.

Figure 27: Representative confocal microscopy images of HCASMC cultured on different
scaffolds for 4 days. Green represents F-actin (phalloidin stained), blue is for nuclei, and
red is for SMC a-actin. Scale bar: 100 pm (A, C, E); 25 pm (B, D, F)
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In addition to cell viability, in vitro vascular tissue engineering requires that cells be
given a more specific level of instruction so that tissue fabrication is successful.95 However, two
interrelated unsolved challenges - regulation of vascular smooth muscle cell phenotype and
synthesis of elastin in engineered vascular tissues - significantly hinder progress in this area.
Unlike cardiac or skeletal muscle cells, VSMCs are not terminally differentiated and are able to
modulate their phenotype in response to changing environmental cues. By understanding and
regulating the local environmental cues required for phenotype modulation, living vascular
substitutes can be engineered.96 When cultured on 3D scaffolds, VSMCs must be first in a
synthetic phenotype for cellular proliferation and ECM secretion to occur and needed for tissue
generation and maturation. The synthetic phenotype is anticipated to accelerate elastin synthesis,
a critical extracellular matrix component that is notably absent in currently engineered vascular
tissues.
In a contractile phenotype VSMCs have a very low proliferative activity and produce
only small amounts of ECM proteins97 while robustly expressing contractile cytoskeletal marker
proteins such as smooth muscle a-actin (SMa-actin); and contract in response to electrical,
chemical and mechanical stimuli.98’ 99 Conversely, in a synthetic phenotype they become
predominantly proliferative suppress the expression of genes that define the contractile
phenotype while rapidly upregulating genes required for proliferation including matrix
metalloproteinases and 1-caldesmon. Figures 27 and 28 presents the double staining for SMaactin from which it can be inferred that HCASMC did not express significant levels of the
contractile protein indicating a predominantly synthetic phenotype. Although the data is limited
to draw a comprehensive conclusion, it suggests that for up to 7 days culture the PEA scaffolds
were able to induce a synthetic phenotype.
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Figure 28: Representative confocal microscopy images of HCASMC cultured on different
scaffolds for 7 days. Green represents F-actin (phalloidin stained), blue is for nuclei, and
red is for SMC a-actin. Scale bar: 100 pm (A, C); 25 pm (B, D)

To evaluate the possibility that reduced contractile marker protein expression may lead to
enhanced elastin gene expression, Western blot analysis was conducted. Figure 29 shows elastin
expression data at 7 days culture from which it is clear that 70PEA-30PCL fibrous scaffold
expressed a significantly higher elastin protein compared with the Pure PEA and pure PCL
controls. This data is consistent with the MTT assay where 70PEA-30PCL had enhanced cell
viability.
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PCL

PEA

70PEA-30PCL

Figure 29: Synthesis of elastin by HCASMCs cultured for 7 days in pure PCL, pure PEA
and 70PEA-30PCL fibrous scaffold as determined by western blot analysis. The densities of
protein expression were quantified and normalized to the expression levels of GAPDH.
Data are all mean ± SEM. Data are mean ±SD for 3 independent experiments.

Taken together, the current study strongly suggest that biodegradable PEA fibrous scaffolds to be
a viable candidate for vascular tissue engineering that may regulate cell phenotype and promote
elastin synthesis.
An appropriately responsive tissue-engineered blood vessel should possess sufficient
mechanical strength, compliance, and suture retention, all of which are governed by the vascular
extracellular matrix. The major matrix components of the vascular wall are elastin and Type I
collagen produced by VSMCs. While collagen provides the stiffness of the vessel wall, elastin
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dictates tissue mechanics at low strains before stiffer collagen fibres are engaged.100 They also
confer elasticity, preventing dynamic tissue creep by stretching under load and recoiling to their
original configurations after the load is released. In addition to the mechanical responsiveness,
elastin is a potent autocrine regulator of vascular smooth muscle cell activity and that this
regulation is important for preventing fibrocellular pathology. Elastin induces actin stress fibre
organization, inhibits proliferation, regulates migration and signals via a non-integrin
heterotrimeric G-protein-coupled pathway.101 Indeed elastin knockout studies and clinical
observations have revealed an essential regulatory function since, in the absence of extracellular
elastin, smooth muscle proliferation stenoses arteries. Thus to ensure appropriate mechanical
function of the vessel and to prevent vessel stenosis, successful vascular tissue replacements
must incorporate an elastic component and as such, represents a critical design goal. The current
approaches to incorporate elastin in tissue-engineered products are to utilize exogenous elastin
scaffold isolated from cadaveric tissues, supplying soluble tropoelastin to a cell culture, and
designing biocompatible synthetic elastic polymers.102, 103 Thus fundamental understanding on
VSMCs phenotype regulation and as well as scaffold material selection is vitally important. The
present study suggests that the phenotype of smooth muscle cells in 3-D engineered vascular
tissues is regulated by the chemistry of the scaffold.
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CHAPTER 4
4 Conclusions and Future Directions
4.1 Conclusions
In this study, attempts to meet the objectives that were outlined in Chapter 1 have been
fulfilled. First, a new polymer with both ester and amino groups consisting of L-alanine, 1,8octanediol and sebacic acid was synthesized successfully, as confirmed by spectroscopic studies.
This polymer, in conjunction with PCL, was used to fabricate 3-D scaffolds by electrospinning.
Although a blend with PCL was finally used in order to achieve the scaffolds, it was shown that
composition ratio had little effect on fibre diameter. Solution concentration was shown to be one
of the most important factors in assessing average fibre size as well as pore size distributions.
With increasing polymer concentration, the fibre size increased, in turn increasing the pore size
of the electrospun mat. The effect of distance to the collector on fibre size was also studied and,
it was shown that increasing the collector distance reduced the average fibre diameter.
Degradation studies revealed that the amount of PEA in the polymer blends had a direct effect on
the eventual degradation rate. Pure PEA showed a mass loss of 33% at the end of one month
incubation in PBS at 37°C. HCASMCs cultured on these materials indicated that the scaffolds
were not cytotoxic. In addition, Western blot analysis confirmed the expression of the protein
elastin. This study suggested a possible utility of the newly synthesized PEA for vascular tissue
engineering applications.
4.2 Future Directions
Given the limited scope and timeline of the project, detailed thermal and physicochemical
analyses of the PEA-PCL blends were not conducted. It is suggested that these studies be carried
out in order to understand the properties of the PEA-PCL blends.
66

As most of the cell culture studies were done on short-term basis, it would be useful to
expand the scope and carry out long-term investigation. Growing the cells on the scaffolds in a
bioreactor would also help assess the viability of the engineered constructs from these scaffolds.
Mechanical properties of the scaffolds such as tensile strength should also be studied. Since
degradation studies in this work focused only on scaffold integrity in PBS, it is important to
conduct an enzymatic study as well. Finally, cell differentiation should also be assessed to
further understand the role of PEAs in tissue engineering for vascular constructs.
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Appendix A: Derivative decomposition temperatures of Polymer blends and Controls
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